**Title:**

A retrospective multicenter analysis of candidaemia among COVID-19 patients during the first UK pandemic wave

**Author list:**

\*Sarah Denny^ 1

Alireza Abdolrasouli^ 2

Tamador Elamin 3

Ximena Gonzalo 2, 4, 5

Scott Pallett 1, 6

Esmita Charani 5

Aatish Patel 1

Hugo Donaldson 2, 3

Stephen Hughes 1

Darius Armstrong-James 4,5

Luke SP Moore 1, 2, 5

Nabeela Mughal 1, 2, 5

**Affiliations:**

1. Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK.

2. North West London Pathology, Fulham Palace Road, London, W6 8RF, UK.

3. West Middlesex University Hospital, Twickenham Road, Isleworth, Middlesex, TW7 6AF

4. Imperial College Healthcare NHS Trust, Praed Street, London W2 1NY, UK.

5. Imperial College London, Department of Infectious Diseases, Flowers Building, Armstrong Road, London, SW7 2AZ, UK.

6. Centre of Defence Pathology, Royal Centre for Defence Medicine, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham, B15 2WB.

**Keywords:**

Microbiology

Candidaemia

Coronavirus

SARS-CoV-2

**\*Corresponding author:**

Dr Sarah Denny, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK. Email: sarahdenny1@nhs.net Telephone: +442033158273

^ First and second author contributed equally.

**Word Count:**

1000

Dear editor

It is with great interest that we read the recent article by De Francesco et al (1), who reported on chlamydia pneumoniae and mycoplasma pneumoniae co-infection in patients with COVID-19. Here, we report our experience with candidaemia co-infection with COVID-19. An increased incidence of candidaemia has been noted in patients with COVID-19 and although patient characteristics, investigations and antifungal therapies have been described (2), to our knowledge, compliance with candidaemia management bundles has not (3).

Here, we present a retrospective review of candidaemias in adult patients (>17 years) with PCR proven COVID-19 between 1st March 2020 - 31st May 2020 across six acute London hospitals. All yeasts isolated from blood cultures were identified by matrix assisted laser desorption/ionisation-time-of-flight (MALDI-TOF) mass spectroscopy (Bruker Daltonik GmbH, Bremen, Germany). Antifungal susceptibility testing was carried out using broth micro-dilution in accordance with EUCAST guidelines (4). An episode of candidaemia was defined as blood culture growth of any *Candida* species.

Eleven patients with concurrent candidaemia and PCR-proven COVID-19 were identified during the study period; ten were male (90.9%), mean age 62 (33-77 years). Underlying comorbidities were predominantly cardiovascular (10/11). Two patients were immunosuppressed (see Table 1), but neutropenia was not identified.

Ten patients (90.9%) were admitted to an intensive care unit (ICU) prior to their candidaemia diagnosis. Of the ICU patients (n=10), all were intubated and ventilated, had an intravascular and urinary catheter and received inotropes. The non-ICU patient also had a urinary catheter. Nine (90%) of the ICU patients received haemofiltration. None of the patients in our cohort received total parenteral nutrition.

All eleven patients received broad-spectrum antibacterials. One patient received prior antifungal treatment in hospital with topical clotrimazole and oral terbinafine for a tinea infection.

The average number of days from PCR-proven COVID-19 to candidaemia was 14.8 days and from ICU admission to candidaemia, 15.5 days (range 6–24 days). Seven out of eleven candidaemias (63.6%) were *C.albican*s, two (18.2%) *C.parapsilosis*, one (9.1%) *C. glabrata* and one (9.1%) *C.dubliniensis*. All isolates were fluconazole susceptible, except one (*Candida glabrata*), which showed intermediate susceptibility, although the patient was successfully treated with azole therapy through dose-optimisation.

An echinocandin was commenced for ten patients, as per local guidelines, pending susceptibility testing. One patient died prior to blood culture positivity and treatment. Four out of ten (40%) patients were switched to fluconazole to complete treatment. In line with recommended practice (3) six out of eleven patients (54.5%) had repeat blood cultures within 48 hours of treatment, eight (72.7%) patients had an echocardiogram, but only one (9.1%) had fundoscopy. Serum (1-3)-β-D-glucan(BDG) testing was performed in 54.4% (6/11) of patients; three were positive(see Table 1).

Intravascular catheters were removed for nine out of ten patients (90%), the last patient dying prior to candidaemia notification. Seven out of nine patients had line tips sent for culture; two were positive for yeasts. One line tip confirmed an identical *Candida* spp., and hence constituted a line infection, but no further identification was available for the second.

Four patients had prior colonization with yeasts; one with the same species as their candidaemia, no further identification was available for the remaining three. Five patients were not colonized and two had an unknown status following transfer from other secondary care providers, developing candidaemia shortly after transfer.

In concordance with Mastrangelo et al (1), there was a high 30-day mortality of 54.4% (6/11) in our patient cohort. The four surviving patients (36.6%) were discharged; average total length of stay 58 days (range 31-78 days). One patient was stepped down after nine weeks in ICU but remained an inpatient until the end of our study period.

Given the high mortality rate, it is important to identify and address modifiable risk factors in an attempt to prevent the occurrence of candidaemia. Firstly, all our patients received broad-spectrum antibacterials, a recognized risk factor for candidaemia (5,6). A recent study from Hughes et al (7) demonstrated a low frequency (3.2%) of early bacterial co-infection in patients hospitalized with COVID-19, suggesting early broad-spectrum antibacterials may not be warranted. Hence, antimicrobial stewardship initiatives to review unnecessary antibacterial use remain important.

Secondly, intravascular catheters are a well-recognised risk factor for candidaemia (5) and over 90% of our patients had these. The incidence of candidaemia observed warrants further consideration, and whilst not compared to pre-COVID-19 incidence (2), may potentially reflect pandemic unique challenges. Examples include increased ICU capacity, redeployment of less-experienced staff to ICU, challenges to aseptic technique with personal protective equipment (PPE), and patients requiring re-positioning to improve oxygenation, thus increasing possibility of line displacement/contamination. Improved aseptic intravascular catheter training focusing on PPE may be beneficial.

In addition, although we were unable to identify urinary catheters as a source in our cohort, they are a recognized risk factor for candidaemia (6) and all patients in our cohort had these.

One patient died prior to candidaemia notification. Time to blood culture positivity may be delayed, particularly for non-albicans candidaemias (8), and delay in treatment is known to increase mortality (9), therefore, non-culture-based diagnostics such as galactomannan antigen and BDG should be combine with clinical data to aid diagnosis (10). 54.4% (n=6) of the patients were tested for BDG, and of those, 50% (n=3) were positive. Although not possible to demonstrate in this patient cohort, an early positive BDG may herald invasive fungal infection, enabling timely initiation of empirical antifungal therapy.

Guidelines for management of candidaemia recommend a care bundle, including repeat blood cultures at 48 hours, echocardiogram, and fundoscopy to identify disseminated infection. In our cohort, only 54.5 % (6/11) of patients had repeat blood cultures within 48 hours, 72.7 % (8/11) an echocardiogram and only 9.1% (1/11) fundoscopy. COVID-19 infection control concerns, patient positioning and PPE, with resultant challenges to ophthalmic examination, may account for the poor fundoscopy compliance, adding further weight to the need for COVID-19 specific practical training.

To conclude, during the ongoing COVID-19 pandemic it remains important to consider modifiable risk factors for candidaemia, non-culture based diagnositics to aid early diagnosis, as well as adherence to established treatment bundles.

**Declarations**

**Acknowledgements**

LSPM acknowledges support from the National Institute of Health Research (NIHR) Imperial Biomedical Research Centre (BRC) and the National Institute for Health Research Health Protection Research Unit (HPRU) in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London in partnership with Public Health England. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, The Wellcome Trust or the UK Department of Health. DAJ is funded by the DHSC Centre for Antimicrobial Optimisation, at Imperial College, London. The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care, NHS, or the National Institute for Health Research. DAJ is also funded by a Cystic Fibrosis Trust Strategic Research Centre (SRC015) and a Wellcome Trust Collaborative Award (219551/Z/19/Z).

**Ethics**

Ethical approval was not required for this service evaluation and audit of practice.

**Authors’ contributions**

SD, AR and NM designed the study methodology. SD, TE and XG collated the data. SD drafted the initial manuscript with all authors contributing significantly to revising this for submission. All authors agreed on the final version for submission to the journal.

**Funding**

This research did not receive any grant from funding agencies in the public or commercial sectors.

**Potential conflicts of interests**

SC has received a research grants from the Scientific Exploration Society.

EC has been paid for consultancy fees by bioMerieux.

SH reports personal fees from Pfizer and Shionogi.

DAJ holds share options in Pulmocide Ltd and has received research grants from Pulmocide Ltd, Gilead Sciences, Astellas and Pfizer. He has received speaker and consultancy fees from Astra-Zeneca, Pfizer, Gilead, and Astellas.

LSPM has consulted for DNAelectronics (2015-18), Dairy Crest (2017–2018), Umovis Lab (2020), bioMerieux (2013-2020), received speaker fees from Profile Pharma (2018) and Pfizer (2018-2020), received research grants from the National Institute for Health Research (2013-2020), CW+ Charity (2018-2020), and Leo Pharma (2016), and received educational support from Eumedica (2016–2018).

NM has received speaker fees from Beyer (2016) and Pfizer (2019) and received educational support from Eumedica (2016) and Baxter (2017).

All other authors have no conflicts of interest to declare.

**Availability of data and materials**

The data analysed during the current study and further details on the assays are available from the corresponding author (SD; [sarahdenny1@nhs.net](mailto:sarahdenny1@nhs.net)) on reasonable request, as long as this meets local ethical and research governance criteria.

**References**

1. De Francesco MA, Poiesi C, Gargiulo F, Bonfanti C, Pollara P, Fiorentini S, Caccuri F, Carta V, Mangeri L, Pellizzeri S, Rizzoni D. Co-infection of Chlamydia pneumoniae and Mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. The Journal of infection. 2021 Jan 19.
2. Mastrangelo A, Germinario BN, Ferrante M, Frangi C, Voti RL, Muccini C, Ripa M, COVID-BioB Study Group. Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020 Oct 30:ciaa1594.
3. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan‐Akdagli S, Bille J. ESCMID\* guideline for the diagnosis and management of Candida diseases 2012: non‐neutropenic adult patients. Clinical Microbiology and Infection. 2012 Dec;18:19-37.
4. EUCAST – antifungal MIC method for yeast 2020 [Available from: [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\_files/AFST/Files/EUCAST\_E\_Def\_7.3.2\_Yeast\_testing\_definitive\_revised\_2020.pdf](about:blank)
5. Barberino MG, Silva N, Rebouças C, Barreiro K, Alcântara AP, Netto EM, Albuquerque L, Brites C. Evaluation of blood stream infections by Candida in three tertiary hospitals in Salvador, Brazil: a case-control study. Brazilian Journal of Infectious Diseases. 2006 Feb;10(1):36-40.
6. Yapar N, Pullukcu H, Avkan-Oguz V, Sayin-Kutlu S, Ertugrul B, Sacar S, Cetin B, Kaya O. Evaluation of species distribution and risk factors of candidemia: a multicenter case-control study. Medical mycology. 2011 Jan 1;49(1):26-31.
7. Hughes S, Troise O, Donaldson H, Mughal N, Moore LS. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clinical Microbiology and Infection. 2020 Oct 1;26(10):1395-9.
8. Fernandez J, Erstad BL, Petty W, Nix DE. Time to positive culture and identification for Candida blood stream infections. Diagnostic microbiology and infectious disease. 2009 Aug 1;64(4):402-7.
9. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial agents and chemotherapy. 2005 Sep 1;49(9):3640-5.
10. Del Bono V, Delfino E, Furfaro E, Mikulska M, Nicco E, Bruzzi P, Mularoni A, Bassetti M, Viscoli C. Clinical performance of the (1, 3)-β-d-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clinical and Vaccine Immunology. 2011 Dec 1;18(12):2113-7.

|  |  |
| --- | --- |
| **Demographics** | N=11 |
| Age, years  Sex, male | 62 (33-77)  10 (90.9%) |
| **Past medical history** |  |
| Type 2 diabetes  Hypercholesterolaemia  Hypertension  Ischaemic Heart Disease  Permanent Pacemaker  Myaesthenia Gravis  Previous solid organ malignancy  Gastro-oesophageal Reflux Disease  Benign prostatic hypertrophy  Hypopituitarism | 8 (72.7 %)  8 (72.7%)  3 (27.3%)  1 (9.1%)  1 (9.1%)  1 (9.1%)  2 (18.2%)  1 (9.1%)  1 (9.1%)  1 (9.1%) |
| **Risk factors for candidaemia** |  |
| Immunosuppression  Broad spectrum antimicrobials  Neutropenic  Intensive care (ICU) admission  Intravenous catheter   * Average catheter day * Number of patients where catheter day unknown   Ventilated  Inotropic support  Haemofiltration  Urinary catheter  Total parenteral nutrition  Candida colonisation   * Yes * No * Unknown | 2 (18.2%) a  11 (100%)  0 (0%)  10 (90.9%)  10 (90.9%)  6.3 (3-9)  4 (40%)  10 (90.9%)  10 (90.9%)  9 (81.8)  11 (100%)  0 (0%)  4  5  2 |
| **Clinical course** |  |
| Days to candidaemia since COVID-19 diagnosis  Days to candidaemia since ICU admission  Repeat blood cultures taken at 48 hours  Days to candidaemia clearance  Non-albicans candidaemia  Beta-D-glucan performed   * positive * negative   Galactomannan performed   * positive * negative   Intravascular catheter removed   * culture confirmation of same Candida spp.   Echocardiogram performed   * positive * negative   Fundoscopy peformed   * positive * negative   Death at 30 days | 14.8 (7-24)  15.5 (6-24)  6 (54.5%)  2.3 (1-3)  4 (36.4%)  6 (54.5%)  3 (50%) b  3 (50%)  5 (45.5%)  0 (0%)  5 (100%)  9 (90%)  1 (10%)  8 (72.7%)  0 (0%)  8 (100%)  1 (9.1%)  0 (0%)  1 (100%)  6 (54.5%) |
| Values are reported as mean and range or frequency (%)  a: One patient received 9mg prednisolone once daily plus 500mg mycophenolate mofetil twice daily for myasthenia gravis A second patient received hydrocortisone 10mg/5mg/5mg for hypopituitarism.  b: Positive results included values of 256 pg/ml, 154 pg/ml and 110 pg/ml | |

**Table 1**: Characteristics of patients with concurrent COVID-19 and candidaemia.